Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults.
Beate Schmoele-Thoma, Martin van Cleeff, Richard N Greenberg, Alejandra Gurtman, Thomas R Jones, Vani Sundaraiyer, William C Gruber, Daniel A Scott
Author Information
Beate Schmoele-Thoma: a Pfizer Vaccine Clinical Research and Development , Pfizer Pharma GmbH , Berlin , Germany. ORCID
Martin van Cleeff: b Triangle Medical Research Associates , Raleigh , NC , USA.
Richard N Greenberg: c Pfizer Vaccine Clinical Research and Development , Pearl River , NY , USA.
Alejandra Gurtman: d Pfizer Vaccines Research , Pearl River , NY , USA.
Thomas R Jones: d Pfizer Vaccines Research , Pearl River , NY , USA.
Vani Sundaraiyer: e Syneos Health , Princeton , NJ , USA.
William C Gruber: d Pfizer Vaccines Research , Pearl River , NY , USA.
Daniel A Scott: d Pfizer Vaccines Research , Pearl River , NY , USA.
Vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) followed ≥ 1 year by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for immunocompetent adults ≥ 65 years of age in the United States. This study assessed antipneumococcal opsonophagocytic activity (OPA) geometric mean titers (GMTs) to PCV13 in PPSV23-naive and PPSV23-preimmunized adults 1 year after a second vaccine dose. Two parent studies were conducted previously: (1) PPSV23 vaccine-naive subjects (60-64 years of age at enrollment) received PCV13 followed by PCV13 or PPSV23 1 year later or PPSV23 followed by PCV13 1 year later; and (2) subjects (≥ 70 years of age at enrollment) vaccinated with PPSV23 ≥ 5 years before study entry received PCV13 or PPSV23 followed by PCV13 1 year later. Overall, 962 subjects (PPSV23-naive, n = 519; PPSV23-preimmunized, n = 443) who received both vaccinations in the parent studies were enrolled. Numerically higher OPA GMTs persisted for at least 1 year after administration of PCV13 as the initial vaccine (PCV13/PPSV23 or PCV13/PCV13) compared with those who received PPSV23 either 1 or 5 years prior (PPSV23/PCV13). This impairment in antibody responses to subsequent PCV13 vaccination produced by initial PPSV23 vaccination persisted for at least 1 year. OPA GMTs were numerically higher for most serotypes 1 year after 2 doses of PCV13 compared with 1 year after the first PCV13 dose. These data suggest PCV13 should be given first if both vaccines are to be administered, higher immune responses were achieved when PCV13 was given first and persisted at least 1 year (ClinicalTrials.gov Identifier: NCT01025336).
